Search Results for: Cancer

23406 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
CREBBP and SMAD4 CREB binding protein SMAD family member 4
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Metabolism of lipids and lipoproteins
  • Signaling by Wnt
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • Pre-NOTCH Transcription and Translation
  • RNF mutants show enhanced WNT signaling and proliferation
  • Signaling by NOTCH1 in Cancer
  • Orphan transporters
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • Factors involved in megakaryocyte development and platelet production
  • Chromatin modifying enzymes
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Activation of gene expression by SREBF (SREBP)
  • Transcriptional activation of mitochondrial biogenesis
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • PPARA activates gene expression
  • Cellular response to hypoxia
  • Organelle biogenesis and maintenance
  • Regulation of Hypoxia-inducible Factor (HIF) by oxygen
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Attenuation phase
  • HATs acetylate histones
  • RORA activates circadian gene expression
  • Regulation of cholesterol biosynthesis by SREBP (SREBF)
  • HSF1-dependent transactivation
  • TRAF3-dependent IRF activation pathway
  • Signaling by NOTCH1
  • Transcriptional regulation of white adipocyte differentiation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Pre-NOTCH Expression and Processing
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Innate Immune System
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Cytosolic sensors of pathogen-associated DNA
  • Cellular response to heat stress
  • REV-ERBA represses gene expression
  • Mitochondrial biogenesis
  • Notch-HLH transcription pathway
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • NOTCH1 Intracellular Domain Regulates Transcription
  • TCF dependent signaling in response to WNT
  • TRAF6 mediated IRF7 activation
  • YAP1- and WWTR1 (TAZ)-stimulated gene expression
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Signaling by WNT in cancer
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Loss of Function of TGFBR2 in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Signaling by BMP
  • Transcriptional regulation of pluripotent stem cells
  • Generic Transcription Pathway
  • Signaling by NODAL
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by Activin
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
CREBBP and CTNNB1 CREB binding protein catenin (cadherin-associated protein), beta 1, 88kDa
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Metabolism of lipids and lipoproteins
  • Signaling by Wnt
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • Pre-NOTCH Transcription and Translation
  • RNF mutants show enhanced WNT signaling and proliferation
  • Signaling by NOTCH1 in Cancer
  • Orphan transporters
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • Factors involved in megakaryocyte development and platelet production
  • Chromatin modifying enzymes
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Activation of gene expression by SREBF (SREBP)
  • Transcriptional activation of mitochondrial biogenesis
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • PPARA activates gene expression
  • Cellular response to hypoxia
  • Organelle biogenesis and maintenance
  • Regulation of Hypoxia-inducible Factor (HIF) by oxygen
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Attenuation phase
  • HATs acetylate histones
  • RORA activates circadian gene expression
  • Regulation of cholesterol biosynthesis by SREBP (SREBF)
  • HSF1-dependent transactivation
  • TRAF3-dependent IRF activation pathway
  • Signaling by NOTCH1
  • Transcriptional regulation of white adipocyte differentiation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Pre-NOTCH Expression and Processing
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Innate Immune System
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Cytosolic sensors of pathogen-associated DNA
  • Cellular response to heat stress
  • REV-ERBA represses gene expression
  • Mitochondrial biogenesis
  • Notch-HLH transcription pathway
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • NOTCH1 Intracellular Domain Regulates Transcription
  • TCF dependent signaling in response to WNT
  • TRAF6 mediated IRF7 activation
  • YAP1- and WWTR1 (TAZ)-stimulated gene expression
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Signaling by WNT in cancer
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • S33 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • truncations of AMER1 destabilize the destruction complex
  • CDO in myogenesis
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Cytosolic sensors of pathogen-associated DNA
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • Myogenesis
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Urea
CREBBP and SMAD2 CREB binding protein SMAD family member 2
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Metabolism of lipids and lipoproteins
  • Signaling by Wnt
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • Pre-NOTCH Transcription and Translation
  • RNF mutants show enhanced WNT signaling and proliferation
  • Signaling by NOTCH1 in Cancer
  • Orphan transporters
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • Factors involved in megakaryocyte development and platelet production
  • Chromatin modifying enzymes
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Activation of gene expression by SREBF (SREBP)
  • Transcriptional activation of mitochondrial biogenesis
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • PPARA activates gene expression
  • Cellular response to hypoxia
  • Organelle biogenesis and maintenance
  • Regulation of Hypoxia-inducible Factor (HIF) by oxygen
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Attenuation phase
  • HATs acetylate histones
  • RORA activates circadian gene expression
  • Regulation of cholesterol biosynthesis by SREBP (SREBF)
  • HSF1-dependent transactivation
  • TRAF3-dependent IRF activation pathway
  • Signaling by NOTCH1
  • Transcriptional regulation of white adipocyte differentiation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Pre-NOTCH Expression and Processing
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Innate Immune System
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Cytosolic sensors of pathogen-associated DNA
  • Cellular response to heat stress
  • REV-ERBA represses gene expression
  • Mitochondrial biogenesis
  • Notch-HLH transcription pathway
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • NOTCH1 Intracellular Domain Regulates Transcription
  • TCF dependent signaling in response to WNT
  • TRAF6 mediated IRF7 activation
  • YAP1- and WWTR1 (TAZ)-stimulated gene expression
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Signaling by WNT in cancer
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Loss of Function of TGFBR2 in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Generic Transcription Pathway
  • Signaling by NODAL
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by Activin
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
CSK and SHC1 c-src tyrosine kinase SHC (Src homology 2 domain containing) transforming protein 1
  • Costimulation by the CD28 family
  • GAB1 signalosome
  • Integrin alphaIIb beta3 signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Signaling by EGFRvIII in Cancer
  • Platelet Aggregation (Plug Formation)
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by EGFR
  • TCR signaling
  • Signaling by EGFR in Cancer
  • PD-1 signaling
  • Platelet activation, signaling and aggregation
  • Phosphorylation of CD3 and TCR zeta chains
  • Adaptive Immune System
  • Signaling by GPCR
  • Signaling by EGFRvIII in Cancer
  • Platelet Aggregation (Plug Formation)
  • SHC1 events in ERBB2 signaling
  • IRE1alpha activates chaperones
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Interleukin receptor SHC signaling
  • SHC-mediated signalling
  • G-protein beta:gamma signalling
  • SHC-related events triggered by IGF1R
  • Signaling by ERBB4
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • GPCR downstream signaling
  • SHC1 events in ERBB4 signaling
  • Signalling to RAS
  • Signaling by EGFR in Cancer
  • Interleukin-2 signaling
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Signalling to ERKs
  • IGF1R signaling cascade
  • XBP1(S) activates chaperone genes
  • G beta:gamma signalling through PI3Kgamma
  • Unfolded Protein Response (UPR)
  • Signaling by Insulin receptor
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • SHC-mediated signalling
  • Integrin alphaIIb beta3 signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Cytokine Signaling in Immune system
  • NGF signalling via TRKA from the plasma membrane
  • SHC-related events
  • Tie2 Signaling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell surface interactions at the vascular wall
  • SHC1 events in EGFR signaling
  • Signal attenuation
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • Interleukin receptor SHC signaling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by EGFRvIII
  • SHC activation
  • Staurosporine
CSNK1A1 and TGFBR1 casein kinase 1, alpha 1 transforming growth factor, beta receptor 1
  • Hedgehog 'off' state
  • misspliced GSK3beta mutants stabilize beta-catenin
  • APC truncation mutants have impaired AXIN binding
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Hedgehog 'on' state
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • deletions in the AMER1 gene destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • AMER1 mutants destabilize the destruction complex
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by Hedgehog
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Activation of SMO
  • Loss of Function of TGFBR2 in Cancer
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Downregulation of TGF-beta receptor signaling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
CSNK1A1 and PPP2R5A casein kinase 1, alpha 1 protein phosphatase 2, regulatory subunit B, alpha
  • Hedgehog 'off' state
  • misspliced GSK3beta mutants stabilize beta-catenin
  • APC truncation mutants have impaired AXIN binding
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Hedgehog 'on' state
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • deletions in the AMER1 gene destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • AMER1 mutants destabilize the destruction complex
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by Hedgehog
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Activation of SMO
  • Mitotic Prometaphase
  • Costimulation by the CD28 family
  • Separation of Sister Chromatids
  • misspliced GSK3beta mutants stabilize beta-catenin
  • APC truncation mutants have impaired AXIN binding
  • T41 mutants of beta-catenin aren't phosphorylated
  • truncated APC mutants destabilize the destruction complex
  • TCF7L2 mutants don't bind CTBP
  • Mitotic Anaphase
  • Signaling by Wnt
  • M Phase
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Degradation of beta-catenin by the destruction complex
  • S37 mutants of beta-catenin aren't phosphorylated
  • RNF mutants show enhanced WNT signaling and proliferation
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • CTLA4 inhibitory signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • Cell Cycle, Mitotic
  • Platelet homeostasis
  • deletions in the AMER1 gene destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • Platelet sensitization by LDL
  • AMER1 mutants destabilize the destruction complex
  • Resolution of Sister Chromatid Cohesion
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Mitotic Metaphase and Anaphase
  • Adaptive Immune System
CSNK1A1 and PDE4D casein kinase 1, alpha 1 phosphodiesterase 4D, cAMP-specific
  • Hedgehog 'off' state
  • misspliced GSK3beta mutants stabilize beta-catenin
  • APC truncation mutants have impaired AXIN binding
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Hedgehog 'on' state
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • deletions in the AMER1 gene destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • AMER1 mutants destabilize the destruction complex
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by Hedgehog
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Activation of SMO
  • Signaling by GPCR
  • GPCR downstream signaling
  • G alpha (s) signalling events
  • Opioid Signalling
  • DARPP-32 events
  • Adenosine monophosphate
  • Dyphylline
  • Ketotifen
  • Iloprost
  • Roflumilast
  • Piclamilast
  • 4-[3-(Cyclopentyloxy)-4-Methoxyphenyl]-2-Pyrrolidinone
  • 3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • 2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol
  • 6-(4-Difluoromethoxy-3-Methoxy-Phenyl)-2h-Pyridazin-3-One
  • 1-(4-Aminophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • (S)-Rolipram
  • Cis-4-Cyano-4-[3-(Cyclopentyloxy)-4-Methoxyphenyl]Cyclohexanecarboxylic Acid
  • (R)-Rolipram
  • 3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • 1-(4-Methoxyphenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • Ibudilast
  • (4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one
  • 3,5-DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
  • 3-ISOBUTYL-1-METHYLXANTHINE
  • 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid
CSNK1A1 and PSEN2 casein kinase 1, alpha 1 presenilin 2
  • Hedgehog 'off' state
  • misspliced GSK3beta mutants stabilize beta-catenin
  • APC truncation mutants have impaired AXIN binding
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Hedgehog 'on' state
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • deletions in the AMER1 gene destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • AMER1 mutants destabilize the destruction complex
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by Hedgehog
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Activation of SMO
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Axon guidance
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Signaling by NOTCH2
  • EPH-ephrin mediated repulsion of cells
  • Signaling by NOTCH1
  • EPH-Ephrin signaling
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Signaling by NOTCH4
  • Regulated proteolysis of p75NTR
  • Signalling by NGF
  • Cell death signalling via NRAGE, NRIF and NADE
  • Signaling by NOTCH
  • p75 NTR receptor-mediated signalling
  • Signaling by ERBB4
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Nuclear signaling by ERBB4
  • NRIF signals cell death from the nucleus
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Signaling by NOTCH3
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
CSNK1A1 and PHLPP1 casein kinase 1, alpha 1 PH domain and leucine rich repeat protein phosphatase 1
  • Hedgehog 'off' state
  • misspliced GSK3beta mutants stabilize beta-catenin
  • APC truncation mutants have impaired AXIN binding
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Hedgehog 'on' state
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • deletions in the AMER1 gene destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • AMER1 mutants destabilize the destruction complex
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by Hedgehog
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Activation of SMO
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • PI3K/AKT activation
  • PI-3K cascade
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signaling by PDGF
  • DAP12 interactions
  • Signalling by NGF
  • GAB1 signalosome
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Negative regulation of the PI3K/AKT network
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
CSNK1A1 and PARK2 casein kinase 1, alpha 1 parkin RBR E3 ubiquitin protein ligase
  • Hedgehog 'off' state
  • misspliced GSK3beta mutants stabilize beta-catenin
  • APC truncation mutants have impaired AXIN binding
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Hedgehog 'on' state
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • deletions in the AMER1 gene destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • AMER1 mutants destabilize the destruction complex
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by Hedgehog
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Activation of SMO
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Class I MHC mediated antigen processing & presentation
  • Adaptive Immune System
CSNK1A1 and MDM4 casein kinase 1, alpha 1 MDM4, p53 regulator
  • Hedgehog 'off' state
  • misspliced GSK3beta mutants stabilize beta-catenin
  • APC truncation mutants have impaired AXIN binding
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Hedgehog 'on' state
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • deletions in the AMER1 gene destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • AMER1 mutants destabilize the destruction complex
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by Hedgehog
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Activation of SMO
CSNK1A1 and YWHAZ casein kinase 1, alpha 1 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta
  • Hedgehog 'off' state
  • misspliced GSK3beta mutants stabilize beta-catenin
  • APC truncation mutants have impaired AXIN binding
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Hedgehog 'on' state
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • deletions in the AMER1 gene destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • AMER1 mutants destabilize the destruction complex
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by Hedgehog
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Activation of SMO
  • Translocation of GLUT4 to the plasma membrane
  • Activation of BH3-only proteins
  • Signaling by Wnt
  • deactivation of the beta-catenin transactivating complex
  • Rap1 signalling
  • RNF mutants show enhanced WNT signaling and proliferation
  • Programmed Cell Death
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Intrinsic Pathway for Apoptosis
  • Regulation of mRNA stability by proteins that bind AU-rich elements
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Cytokine Signaling in Immune system
  • Activation of BAD and translocation to mitochondria
  • Signaling by Interleukins
  • TCF dependent signaling in response to WNT
  • KSRP destabilizes mRNA
  • GP1b-IX-V activation signalling
  • Signaling by WNT in cancer
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Adaptive Immune System
CSNK1A1 and TP53 casein kinase 1, alpha 1 tumor protein p53
  • Hedgehog 'off' state
  • misspliced GSK3beta mutants stabilize beta-catenin
  • APC truncation mutants have impaired AXIN binding
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Hedgehog 'on' state
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • deletions in the AMER1 gene destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • AMER1 mutants destabilize the destruction complex
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by Hedgehog
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Activation of SMO
  • Cellular Senescence
  • Activation of BH3-only proteins
  • p53-Dependent G1/S DNA damage checkpoint
  • Oncogene Induced Senescence
  • p53-Dependent G1 DNA Damage Response
  • Formation of Senescence-Associated Heterochromatin Foci (SAHF)
  • Pre-NOTCH Transcription and Translation
  • Stabilization of p53
  • Transcriptional activation of p53 responsive genes
  • Programmed Cell Death
  • Pre-NOTCH Expression and Processing
  • G1/S DNA Damage Checkpoints
  • Intrinsic Pathway for Apoptosis
  • Transcriptional activation of cell cycle inhibitor p21
  • DNA Damage/Telomere Stress Induced Senescence
  • Signaling by NOTCH
  • Factors involved in megakaryocyte development and platelet production
  • Activation of NOXA and translocation to mitochondria
  • Oxidative Stress Induced Senescence
  • Autodegradation of the E3 ubiquitin ligase COP1
  • Activation of PUMA and translocation to mitochondria
  • Cell Cycle Checkpoints
CSNK1A1 and AXIN1 casein kinase 1, alpha 1 axin 1
  • Hedgehog 'off' state
  • misspliced GSK3beta mutants stabilize beta-catenin
  • APC truncation mutants have impaired AXIN binding
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Hedgehog 'on' state
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • deletions in the AMER1 gene destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • AMER1 mutants destabilize the destruction complex
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by Hedgehog
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Activation of SMO
  • misspliced GSK3beta mutants stabilize beta-catenin
  • APC truncation mutants have impaired AXIN binding
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • deletions in the AMER1 gene destabilize the destruction complex
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • degradation of AXIN
  • Signaling by WNT in cancer
CSNK1A1 and PPP1CC casein kinase 1, alpha 1 protein phosphatase 1, catalytic subunit, gamma isozyme
  • Hedgehog 'off' state
  • misspliced GSK3beta mutants stabilize beta-catenin
  • APC truncation mutants have impaired AXIN binding
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Hedgehog 'on' state
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • deletions in the AMER1 gene destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • AMER1 mutants destabilize the destruction complex
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by Hedgehog
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Activation of SMO
  • Loss of Function of TGFBR2 in Cancer
  • Mitotic Prometaphase
  • Metabolism of lipids and lipoproteins
  • Separation of Sister Chromatids
  • Downregulation of TGF-beta receptor signaling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • Mitotic Anaphase
  • TGFBR1 LBD Mutants in Cancer
  • M Phase
  • Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Lipid digestion, mobilization, and transport
  • Cell Cycle, Mitotic
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • Resolution of Sister Chromatid Cohesion
  • Mitotic Metaphase and Anaphase
  • SMAD4 MH2 Domain Mutants in Cancer
  • 9,10-Deepithio-9,10-Didehydroacanthifolicin
  • Calyculin A
  • (2S,5R,8S,11R,12S,15S,18S,19S,E)-8-ISOBUTYL-18-((5S,6S)-6-METHOXY-3,5-DIMETHYL-7-PHENYLHEPTYL)-1,2,5,12,15,19-HEXAMETHYL-3,6,9,13,16,20,25-HEPTAOXO-1,4,7,10,14,17,21-HEPTAAZACYCLOPENTACOS-21-ENE-11,22-DICARBOXYLIC ACID
  • Motuporin
CSNK1E and AXIN2 casein kinase 1, epsilon axin 2
  • Organelle biogenesis and maintenance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • G2/M Transition
  • Assembly of the primary cilium
  • Signaling by Wnt
  • Regulation of PLK1 Activity at G2/M Transition
  • Anchoring of the basal body to the plasma membrane
  • Cell Cycle, Mitotic
  • WNT mediated activation of DVL
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • Loss of Nlp from mitotic centrosomes
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Centrosome maturation
  • Signaling by WNT in cancer
  • Mitotic G2-G2/M phases
  • Recruitment of mitotic centrosome proteins and complexes
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • formation of the beta-catenin:TCF transactivating complex
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • degradation of AXIN
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • Signaling by WNT in cancer
CSNK2A1 and TCF7L2 casein kinase 2, alpha 1 polypeptide transcription factor 7-like 2 (T-cell specific, HMG-box)
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • S37 mutants of beta-catenin aren't phosphorylated
  • Peptide hormone metabolism
  • Degradation of beta-catenin by the destruction complex
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Incretin synthesis, secretion, and inactivation
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
CSNK2A1 and PRKACB casein kinase 2, alpha 1 polypeptide protein kinase, cAMP-dependent, catalytic, beta
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • Signaling by GPCR
  • Ca-dependent events
  • CaM pathway
  • Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
  • Metabolism of lipids and lipoproteins
  • Integration of energy metabolism
  • Hedgehog 'off' state
  • Phospholipase C-mediated cascade
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • Gluconeogenesis
  • Glucose metabolism
  • DAP12 signaling
  • Rap1 signalling
  • Myoclonic epilepsy of Lafora
  • Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
  • Glycogen storage diseases
  • PKA-mediated phosphorylation of key metabolic factors
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Glucagon signaling in metabolic regulation
  • Signaling by PDGF
  • Calmodulin induced events
  • DAP12 interactions
  • PKA-mediated phosphorylation of CREB
  • Opioid Signalling
  • PKA activation
  • Aquaporin-mediated transport
  • Factors involved in megakaryocyte development and platelet production
  • CREB phosphorylation through the activation of Adenylate Cyclase
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • PKA-mediated phosphorylation of CREB
  • Signaling by VEGF
  • Downstream signal transduction
  • Calmodulin induced events
  • Signaling by EGFR in Cancer
  • PKA activation
  • Metabolism of carbohydrates
  • Transmission across Chemical Synapses
  • Adaptive Immune System
  • VEGFA-VEGFR2 Pathway
  • DAG and IP3 signaling
  • CaM pathway
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • Downstream signaling of activated FGFR
  • DARPP-32 events
  • Post NMDA receptor activation events
  • Innate Immune System
  • PKA activation in glucagon signalling
  • Signalling by NGF
  • PLC beta mediated events
  • Vasopressin regulates renal water homeostasis via Aquaporins
  • Regulation of insulin secretion
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Lipid digestion, mobilization, and transport
  • NGF signalling via TRKA from the plasma membrane
  • G-protein mediated events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • PLC-gamma1 signalling
  • Signaling by Hedgehog
  • Degradation of GLI1 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
CSNK2A1 and CTNNB1 casein kinase 2, alpha 1 polypeptide catenin (cadherin-associated protein), beta 1, 88kDa
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • S33 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • truncations of AMER1 destabilize the destruction complex
  • CDO in myogenesis
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Cytosolic sensors of pathogen-associated DNA
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • Myogenesis
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
  • Urea
CSNK2A1 and PSMA4 casein kinase 2, alpha 1 polypeptide proteasome (prosome, macropain) subunit, alpha type, 4
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • Hedgehog 'off' state
  • misspliced GSK3beta mutants stabilize beta-catenin
  • Hh ligand biogenesis disease
  • T41 mutants of beta-catenin aren't phosphorylated
  • Downstream signaling events of B Cell Receptor (BCR)
  • Degradation of beta-catenin by the destruction complex
  • Stabilization of p53
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • Removal of licensing factors from origins
  • Switching of origins to a post-replicative state
  • Mitotic G1-G1/S phases
  • Regulation of mRNA stability by proteins that bind AU-rich elements
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • DNA Replication Pre-Initiation
  • S45 mutants of beta-catenin aren't phosphorylated
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Regulation of APC/C activators between G1/S and early anaphase
  • SCF(Skp2)-mediated degradation of p27/p21
  • deletions in the AMER1 gene destabilize the destruction complex
  • Autodegradation of the E3 ubiquitin ligase COP1
  • AMER1 mutants destabilize the destruction complex
  • Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
  • APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint
  • PCP/CE pathway
  • Adaptive Immune System
  • CDK-mediated phosphorylation and removal of Cdc6
  • Hedgehog ligand biogenesis
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Separation of Sister Chromatids
  • HIV Infection
  • Ubiquitin-dependent degradation of Cyclin D
  • APC truncation mutants have impaired AXIN binding
  • Assembly of the pre-replicative complex
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • p53-Dependent G1 DNA Damage Response
  • S37 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • p53-Independent DNA Damage Response
  • p53-Independent G1/S DNA damage checkpoint
  • G1/S DNA Damage Checkpoints
  • Vpu mediated degradation of CD4
  • Synthesis of DNA
  • M/G1 Transition
  • Ubiquitin-dependent degradation of Cyclin D1
  • TCF dependent signaling in response to WNT
  • SCF-beta-TrCP mediated degradation of Emi1
  • degradation of AXIN
  • Signaling by Hedgehog
  • Regulation of mitotic cell cycle
  • Degradation of GLI1 by the proteasome
  • degradation of DVL
  • Cell Cycle Checkpoints
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Regulation of Apoptosis
  • Degradation of GLI2 by the proteasome
  • Signaling by the B Cell Receptor (BCR)
  • Vif-mediated degradation of APOBEC3G
  • Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
  • p53-Dependent G1/S DNA damage checkpoint
  • truncated APC mutants destabilize the destruction complex
  • TCF7L2 mutants don't bind CTBP
  • Signaling by Wnt
  • Cyclin E associated events during G1/S transition
  • APC/C:Cdc20 mediated degradation of Securin
  • AUF1 (hnRNP D0) destabilizes mRNA
  • CDK-mediated phosphorylation and removal of Cdc6
  • RNF mutants show enhanced WNT signaling and proliferation
  • G1/S Transition
  • truncations of AMER1 destabilize the destruction complex
  • Processing-defective Hh variants abrogate ligand secretion
  • Host Interactions of HIV factors
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • Regulation of activated PAK-2p34 by proteasome mediated degradation
  • AXIN missense mutants destabilize the destruction complex
  • S Phase
  • APC/C-mediated degradation of cell cycle proteins
  • Cyclin A:Cdk2-associated events at S phase entry
  • SCF(Skp2)-mediated degradation of p27/p21
  • Mitotic Metaphase and Anaphase
  • Regulation of ornithine decarboxylase (ODC)
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Orc1 removal from chromatin
  • Mitotic Anaphase
  • M Phase
  • APC truncation mutants are not K63 polyubiquitinated
  • Metabolism of amino acids and derivatives
  • Hedgehog 'on' state
  • Programmed Cell Death
  • Class I MHC mediated antigen processing & presentation
  • Regulation of DNA replication
  • Cell Cycle, Mitotic
  • beta-catenin independent WNT signaling
  • Orc1 removal from chromatin
  • Activation of NF-kappaB in B cells
  • Asymmetric localization of PCP proteins
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Cross-presentation of soluble exogenous antigens (endosomes)
  • Antigen processing-Cross presentation
  • CDT1 association with the CDC6:ORC:origin complex
  • ER-Phagosome pathway
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid

Page 32 out of 1171 pages